BR112015022513A2 - produto e método para tratamento de diarreia - Google Patents

produto e método para tratamento de diarreia

Info

Publication number
BR112015022513A2
BR112015022513A2 BR112015022513A BR112015022513A BR112015022513A2 BR 112015022513 A2 BR112015022513 A2 BR 112015022513A2 BR 112015022513 A BR112015022513 A BR 112015022513A BR 112015022513 A BR112015022513 A BR 112015022513A BR 112015022513 A2 BR112015022513 A2 BR 112015022513A2
Authority
BR
Brazil
Prior art keywords
product
treating diarrhea
patient
receptor antagonist
diarrhea
Prior art date
Application number
BR112015022513A
Other languages
English (en)
Portuguese (pt)
Inventor
B Hogan Ii Reed
Original Assignee
Maregade Rx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maregade Rx Llc filed Critical Maregade Rx Llc
Priority to BR122017004716-7A priority Critical patent/BR122017004716A2/pt
Publication of BR112015022513A2 publication Critical patent/BR112015022513A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015022513A 2013-03-14 2014-03-14 produto e método para tratamento de diarreia BR112015022513A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122017004716-7A BR122017004716A2 (pt) 2013-03-14 2014-03-14 Composição farmacêutica para tratamento de diarreia, e uso de antagonista do receptor de h1 e de antagonista do receptor de h2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782608P 2013-03-14 2013-03-14
PCT/US2014/027323 WO2014152420A2 (en) 2013-03-14 2014-03-14 Product and method for treating diarrhea

Publications (1)

Publication Number Publication Date
BR112015022513A2 true BR112015022513A2 (pt) 2017-07-18

Family

ID=50680150

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015022513A BR112015022513A2 (pt) 2013-03-14 2014-03-14 produto e método para tratamento de diarreia
BR122017004716-7A BR122017004716A2 (pt) 2013-03-14 2014-03-14 Composição farmacêutica para tratamento de diarreia, e uso de antagonista do receptor de h1 e de antagonista do receptor de h2

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122017004716-7A BR122017004716A2 (pt) 2013-03-14 2014-03-14 Composição farmacêutica para tratamento de diarreia, e uso de antagonista do receptor de h1 e de antagonista do receptor de h2

Country Status (20)

Country Link
US (4) US9717726B2 (https=)
EP (3) EP3269364B1 (https=)
JP (4) JP6313417B2 (https=)
KR (4) KR20200100211A (https=)
CN (2) CN105324112B (https=)
AU (3) AU2014239878B2 (https=)
BR (2) BR112015022513A2 (https=)
CA (1) CA2906005C (https=)
DK (1) DK2968205T3 (https=)
ES (2) ES2743604T3 (https=)
HK (1) HK1247557B (https=)
HU (1) HUE035201T2 (https=)
IL (3) IL273377B2 (https=)
MX (2) MX366329B (https=)
MY (1) MY175326A (https=)
PL (1) PL2968205T3 (https=)
PT (1) PT2968205T (https=)
RU (1) RU2015143475A (https=)
WO (1) WO2014152420A2 (https=)
ZA (1) ZA201708539B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
WO2015073573A1 (en) * 2013-11-14 2015-05-21 Jacobs Michael M Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
EP3558296B1 (en) * 2016-12-23 2023-06-28 Maregade RX, LLC Low dose product and method for treating diarrhea
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi
US11424105B2 (en) * 2019-08-05 2022-08-23 Hitachi High-Tech Corporation Plasma processing apparatus
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
US12586760B2 (en) 2021-08-23 2026-03-24 Hitachi High-Tech Corporation Plasma processing apparatus and plasma processing method
US20240277700A1 (en) * 2021-09-22 2024-08-22 II Reed B. Hogan Compositions and methods for treating and preventing interstitial cystitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5096894A (en) * 1990-04-03 1992-03-17 Bristol-Myers Squibb Company Rice dextrin oral rehydration solution
AU7255094A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-antihistamine combinations
US6264984B1 (en) * 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
AU2100402A (en) 2000-11-30 2002-06-11 Bio Balance Corp Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
CA2690483C (en) * 2001-11-23 2012-07-24 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
SE528789C2 (sv) 2004-09-10 2007-02-13 Sandvik Intellectual Property PVD-belagt skär av hårdmetall samt sätt att tillverka detta
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
EP2526938A3 (en) 2007-02-12 2013-06-12 Mike Nicolaou Histidine decarboxylase inhibitor sole or combined with a leukotriene receptor antagonist, an anti-H1 and/or an anti-H2 to treat COPD or gastrointestinal disorders.
CA2721133C (en) * 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN105051192B (zh) 2012-11-13 2020-04-17 科迪艾克生物科学公司 治疗剂的递送
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
EP3558296B1 (en) 2016-12-23 2023-06-28 Maregade RX, LLC Low dose product and method for treating diarrhea

Also Published As

Publication number Publication date
US20190038619A1 (en) 2019-02-07
AU2019201412A1 (en) 2019-03-21
CA2906005A1 (en) 2014-09-25
MX2015011885A (es) 2016-05-16
EP3269364B1 (en) 2019-05-29
EP3269364A1 (en) 2018-01-17
CA2906005C (en) 2021-12-28
KR20200100211A (ko) 2020-08-25
EP2968205B1 (en) 2017-10-11
KR102449977B1 (ko) 2022-09-30
AU2017251701A1 (en) 2017-11-09
CN105324112B (zh) 2018-08-17
IL273377A (en) 2020-05-31
WO2014152420A2 (en) 2014-09-25
MY175326A (en) 2020-06-19
ZA201708539B (en) 2019-05-29
US11058681B2 (en) 2021-07-13
JP6790140B2 (ja) 2020-11-25
HK1213205A1 (en) 2016-06-30
HK1247557B (en) 2020-07-03
IL241372A0 (en) 2015-11-30
US20170049770A1 (en) 2017-02-23
WO2014152420A3 (en) 2014-11-20
RU2015143475A (ru) 2017-04-20
MX366329B (es) 2019-07-05
ES2743604T3 (es) 2020-02-20
EP3581205A2 (en) 2019-12-18
IL273377B1 (en) 2023-06-01
US9717726B2 (en) 2017-08-01
CN105324112A (zh) 2016-02-10
AU2014239878B2 (en) 2017-08-24
KR101884506B1 (ko) 2018-08-01
KR20210021606A (ko) 2021-02-26
PL2968205T3 (pl) 2018-03-30
CN108939076A (zh) 2018-12-07
DK2968205T3 (da) 2017-11-27
JP2016513692A (ja) 2016-05-16
JP2018135340A (ja) 2018-08-30
IL256300B (en) 2020-04-30
KR20150139535A (ko) 2015-12-11
EP2968205A2 (en) 2016-01-20
JP2019089796A (ja) 2019-06-13
MX350814B (es) 2017-09-21
AU2014239878A1 (en) 2015-10-15
JP2021046400A (ja) 2021-03-25
HUE035201T2 (hu) 2018-05-02
ES2655505T3 (es) 2018-02-20
IL241372B (en) 2018-06-28
JP6473254B2 (ja) 2019-02-20
US10034875B2 (en) 2018-07-31
PT2968205T (pt) 2018-01-05
IL273377B2 (en) 2023-10-01
US20140275116A1 (en) 2014-09-18
IL256300A (en) 2018-02-28
BR122017004716A2 (pt) 2019-07-30
AU2017251701B2 (en) 2019-03-14
US20220047583A1 (en) 2022-02-17
KR20180088514A (ko) 2018-08-03
JP6313417B2 (ja) 2018-04-18
EP3581205A3 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
BR112015022513A2 (pt) produto e método para tratamento de diarreia
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112015026660A2 (pt) ligas metálicas aperfeiçoadas para dispositivos médicos
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
BR112015020466A2 (pt) inibidores de cdc7
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017010440A2 (pt) administração sublingual de riluzol
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
PE20150020A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
BR112014000889A2 (pt) tratamento para hipoxia
BR112016012248A2 (pt) método de tratamento de nefropatia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.